WilmerHale Represents Volastra Therapeutics in $60M Series A Financing

WilmerHale Represents Volastra Therapeutics in $60M Series A Financing

Client News

Related Solutions

Helping clients launch their businesses and transform their innovative ideas into successful companies.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

WilmerHale represented Volastra Therapeutics, a clinical stage cancer biotechnology company focused on exploiting chromosomal instability (CIN), in closing its $60 million Series A financing, which was led by founding investors Polaris Partners and ARCH Venture Partners alongside Eli Lilly and Company. Also participating were Droia Ventures, Catalio Capital Management, Vida Ventures, Cornell University, and Meyers Ventures LLC, an affiliate of Ocean Road Advisors.  Volastra Therapeutics also concurrently completed an in-license of Amgen’s sovilnesib (AMG650), an oral, first-in-class small molecule inhibitor of KIF18A.

The WilmerHale legal team representing Volastra Therapeutics for the Series A financing was led by Cynthia Mazareas and included Hilary Baker-Jennings, Sam Rothberg, Alex Bloom and Cynthia Sullivan.

 

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel